Global Poultry Live Attenuated Vaccine Market Outlook, InDepth Analysis & Forecast to 2032家禽用弱毒生ワクチンの世界市場 2026-2032年 The global Poultry Live Attenuated Vaccine market is projected to grow from US$ 1209 million in 2025 to US$ 1623 million by 2032, at a CAGR of 4.5% (2026-2032), driven by critical product segments ... もっと見る
図表リストList of TablesTable 1. Global Poultry Live Attenuated Vaccine Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million) Table 2. Global Poultry Live Attenuated Vaccine Market Size Growth Rate by Antigen Combination, 2021 vs 2025 vs 2032 (US$ Million) Table 3. Global Poultry Live Attenuated Vaccine Market Size Growth Rate by Dosage Form, 2021 vs 2025 vs 2032 (US$ Million) Table 4. Global Poultry Live Attenuated Vaccine Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million) Table 5. Global Poultry Live Attenuated Vaccine Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million) Table 6. Global Poultry Live Attenuated Vaccine Revenue by Region (US$ Million), 2021-2026 Table 7. Global Poultry Live Attenuated Vaccine Revenue by Region (US$ Million), 2027-2032 Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million) Table 9. Global Poultry Live Attenuated Vaccine Revenue by Players (US$ Million), 2021-2026 Table 10. Global Poultry Live Attenuated Vaccine Revenue-Based Market Share by Players (2021-2026) Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue) Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Poultry Live Attenuated Vaccine Revenue, 2025 Table 13. Global Poultry Live Attenuated Vaccine Average Gross Margin (%) by Player (2021 vs 2025) Table 14. Global Poultry Live Attenuated Vaccine Companies Headquarters Table 15. Global Poultry Live Attenuated Vaccine Market Concentration Ratio (CR5) Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment Table 18. Global Poultry Live Attenuated Vaccine Revenue by Type (US$ Million), 2021-2026 Table 19. Global Poultry Live Attenuated Vaccine Revenue by Type (US$ Million), 2027-2032 Table 20. Global Poultry Live Attenuated Vaccine Revenue by Antigen Combination (US$ Million), 2021-2026 Table 21. Global Poultry Live Attenuated Vaccine Revenue by Antigen Combination (US$ Million), 2027-2032 Table 22. Global Poultry Live Attenuated Vaccine Revenue by Dosage Form (US$ Million), 2021-2026 Table 23. Global Poultry Live Attenuated Vaccine Revenue by Dosage Form (US$ Million), 2027-2032 Table 24. Key Product Attributes and Differentiation Table 25. Global Poultry Live Attenuated Vaccine Revenue by Application (US$ Million), 2021-2026 Table 26. Global Poultry Live Attenuated Vaccine Revenue by Application (US$ Million), 2027-2032 Table 27. Poultry Live Attenuated Vaccine High-Growth Sectors Demand CAGR (2026-2032) Table 28. Top Customers by Region Table 29. Top Customers by Application Table 30. North America Poultry Live Attenuated Vaccine Growth Accelerators and Market Barriers Table 31. North America Poultry Live Attenuated Vaccine Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million) Table 32. Europe Poultry Live Attenuated Vaccine Growth Accelerators and Market Barriers Table 33. Europe Poultry Live Attenuated Vaccine Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million) Table 34. Asia-Pacific Poultry Live Attenuated Vaccine Growth Accelerators and Market Barriers Table 35. Asia-Pacific Poultry Live Attenuated Vaccine Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million) Table 36. Central and South America Poultry Live Attenuated Vaccine Investment Opportunities and Key Challenges Table 37. Central and South America Poultry Live Attenuated Vaccine Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million) Table 38. Middle East and Africa Poultry Live Attenuated Vaccine Investment Opportunities and Key Challenges Table 39. Middle East and Africa Poultry Live Attenuated Vaccine Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million) Table 40. MSD Animal Health(Merck) Corporation Information Table 41. MSD Animal Health(Merck) Description and Major Businesses Table 42. MSD Animal Health(Merck) Product Features and Attributes Table 43. MSD Animal Health(Merck) Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. MSD Animal Health(Merck) Revenue Proportion by Product in 2025 Table 45. MSD Animal Health(Merck) Revenue Proportion by Application in 2025 Table 46. MSD Animal Health(Merck) Revenue Proportion by Geographic Area in 2025 Table 47. MSD Animal Health(Merck) Poultry Live Attenuated Vaccine SWOT Analysis Table 48. MSD Animal Health(Merck) Recent Developments Table 49. Zoetis Corporation Information Table 50. Zoetis Description and Major Businesses Table 51. Zoetis Product Features and Attributes Table 52. Zoetis Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Zoetis Revenue Proportion by Product in 2025 Table 54. Zoetis Revenue Proportion by Application in 2025 Table 55. Zoetis Revenue Proportion by Geographic Area in 2025 Table 56. Zoetis Poultry Live Attenuated Vaccine SWOT Analysis Table 57. Zoetis Recent Developments Table 58. Boehringer Ingelheim Corporation Information Table 59. Boehringer Ingelheim Description and Major Businesses Table 60. Boehringer Ingelheim Product Features and Attributes Table 61. Boehringer Ingelheim Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Boehringer Ingelheim Revenue Proportion by Product in 2025 Table 63. Boehringer Ingelheim Revenue Proportion by Application in 2025 Table 64. Boehringer Ingelheim Revenue Proportion by Geographic Area in 2025 Table 65. Boehringer Ingelheim Poultry Live Attenuated Vaccine SWOT Analysis Table 66. Boehringer Ingelheim Recent Developments Table 67. Ceva Santé Animale Corporation Information Table 68. Ceva Santé Animale Description and Major Businesses Table 69. Ceva Santé Animale Product Features and Attributes Table 70. Ceva Santé Animale Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Ceva Santé Animale Revenue Proportion by Product in 2025 Table 72. Ceva Santé Animale Revenue Proportion by Application in 2025 Table 73. Ceva Santé Animale Revenue Proportion by Geographic Area in 2025 Table 74. Ceva Santé Animale Poultry Live Attenuated Vaccine SWOT Analysis Table 75. Ceva Santé Animale Recent Developments Table 76. Elanco Animal Health Corporation Information Table 77. Elanco Animal Health Description and Major Businesses Table 78. Elanco Animal Health Product Features and Attributes Table 79. Elanco Animal Health Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Elanco Animal Health Revenue Proportion by Product in 2025 Table 81. Elanco Animal Health Revenue Proportion by Application in 2025 Table 82. Elanco Animal Health Revenue Proportion by Geographic Area in 2025 Table 83. Elanco Animal Health Poultry Live Attenuated Vaccine SWOT Analysis Table 84. Elanco Animal Health Recent Developments Table 85. HIPRA Corporation Information Table 86. HIPRA Description and Major Businesses Table 87. HIPRA Product Features and Attributes Table 88. HIPRA Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. HIPRA Recent Developments Table 90. Vaxxinova Corporation Information Table 91. Vaxxinova Description and Major Businesses Table 92. Vaxxinova Product Features and Attributes Table 93. Vaxxinova Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Vaxxinova Recent Developments Table 95. QYH Biotech Corporation Information Table 96. QYH Biotech Description and Major Businesses Table 97. QYH Biotech Product Features and Attributes Table 98. QYH Biotech Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. QYH Biotech Recent Developments Table 100. Pulike Corporation Information Table 101. Pulike Description and Major Businesses Table 102. Pulike Product Features and Attributes Table 103. Pulike Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. Pulike Recent Developments Table 105. Harbin Pharmaceutical Group Corporation Information Table 106. Harbin Pharmaceutical Group Description and Major Businesses Table 107. Harbin Pharmaceutical Group Product Features and Attributes Table 108. Harbin Pharmaceutical Group Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. Harbin Pharmaceutical Group Recent Developments Table 110. Nisseiken Corporation Information Table 111. Nisseiken Description and Major Businesses Table 112. Nisseiken Product Features and Attributes Table 113. Nisseiken Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. Nisseiken Recent Developments Table 115. Hester Biosciences Corporation Information Table 116. Hester Biosciences Description and Major Businesses Table 117. Hester Biosciences Product Features and Attributes Table 118. Hester Biosciences Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. Hester Biosciences Recent Developments Table 120. Phibro Animal Health Corporation Information Table 121. Phibro Animal Health Description and Major Businesses Table 122. Phibro Animal Health Product Features and Attributes Table 123. Phibro Animal Health Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. Phibro Animal Health Recent Developments Table 125. CAVAC Corporation Information Table 126. CAVAC Description and Major Businesses Table 127. CAVAC Product Features and Attributes Table 128. CAVAC Revenue (US$ Million) and Gross Margin (2021-2026) Table 129. CAVAC Recent Developments Table 130. KBNP Corporation Information Table 131. KBNP Description and Major Businesses Table 132. KBNP Product Features and Attributes Table 133. KBNP Revenue (US$ Million) and Gross Margin (2021-2026) Table 134. KBNP Recent Developments Table 135. Bioveta Corporation Information Table 136. Bioveta Description and Major Businesses Table 137. Bioveta Product Features and Attributes Table 138. Bioveta Revenue (US$ Million) and Gross Margin (2021-2026) Table 139. Bioveta Recent Developments Table 140. Jilin Zhengye Corporation Information Table 141. Jilin Zhengye Description and Major Businesses Table 142. Jilin Zhengye Product Features and Attributes Table 143. Jilin Zhengye Revenue (US$ Million) and Gross Margin (2021-2026) Table 144. Jilin Zhengye Recent Developments Table 145. Yebio Corporation Information Table 146. Yebio Description and Major Businesses Table 147. Yebio Product Features and Attributes Table 148. Yebio Revenue (US$ Million) and Gross Margin (2021-2026) Table 149. Yebio Recent Developments Table 150. Sinder Corporation Information Table 151. Sinder Description and Major Businesses Table 152. Sinder Product Features and Attributes Table 153. Sinder Revenue (US$ Million) and Gross Margin (2021-2026) Table 154. Sinder Recent Developments Table 155. Guangzhou South China Biological Medicine Corporation Information Table 156. Guangzhou South China Biological Medicine Description and Major Businesses Table 157. Guangzhou South China Biological Medicine Product Features and Attributes Table 158. Guangzhou South China Biological Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 159. Guangzhou South China Biological Medicine Recent Developments Table 160. Technologies, Platforms and Infrastructure Table 161. Distributors List Table 162. Market Trends and Market Evolution Table 163. Market Drivers and Opportunities Table 164. Market Challenges, Risks, and Restraints Table 165. Research Programs/Design for This Report Table 166. Key Data Information from Secondary Sources Table 167. Key Data Information from Primary Sources List of Figures Figure 1. Global Poultry Live Attenuated Vaccine Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million) Figure 2. Live Attenuated Viral Vaccines Product Picture Figure 3. Live Attenuated Bacterial Vaccines Product Picture Figure 4. Others Product Picture Figure 5. Global Poultry Live Attenuated Vaccine Market Size Growth Rate by Antigen Combination, 2021 vs 2025 vs 2032 (US$ Million) Figure 6. Monovalent Live Attenuated Vaccines Product Picture Figure 7. Bivalent Live Attenuated Vaccines Product Picture Figure 8. Multivalent Live Attenuated Vaccines Product Picture Figure 9. Global Poultry Live Attenuated Vaccine Market Size Growth Rate by Dosage Form, 2021 vs 2025 vs 2032 (US$ Million) Figure 10. Lyophilized Live Attenuated Vaccines Product Picture Figure 11. Frozen Live Attenuated Vaccines Product Picture Figure 12. Liquid Live Attenuated Vaccines Product Picture Figure 13. Global Poultry Live Attenuated Vaccine Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million) Figure 14. Broiler Farming Figure 15. Layer Farming Figure 16. Breeder Farming Figure 17. Others Figure 18. Poultry Live Attenuated Vaccine Report Years Considered Figure 19. Global Poultry Live Attenuated Vaccine Revenue, (US$ Million), 2021 vs 2025 vs 2032 Figure 20. Global Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032 Figure 21. Global Poultry Live Attenuated Vaccine Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million) Figure 22. Global Poultry Live Attenuated Vaccine Revenue-Based Market Share by Region (2021-2032) Figure 23. Global Poultry Live Attenuated Vaccine Revenue-Based Market Share Ranking (2025) Figure 24. Tier Distribution by Revenue Contribution (2021 vs 2025) Figure 25. Live Attenuated Viral Vaccines Revenue-Based Market Share by Player in 2025 Figure 26. Live Attenuated Bacterial Vaccines Revenue-Based Market Share by Player in 2025 Figure 27. Others Revenue-Based Market Share by Player in 2025 Figure 28. Global Poultry Live Attenuated Vaccine Revenue-Based Market Share by Type (2021-2032) Figure 29. Global Poultry Live Attenuated Vaccine Revenue-Based Market Share by Antigen Combination (2021-2032) Figure 30. Global Poultry Live Attenuated Vaccine Revenue-Based Market Share by Dosage Form (2021-2032) Figure 31. Global Poultry Live Attenuated Vaccine Revenue-Based Market Share by Application (2021-2032) Figure 32. North America Poultry Live Attenuated Vaccine Revenue YoY (US$ Million), 2021-2032 Figure 33. North America Top 5 Players Poultry Live Attenuated Vaccine Revenue (US$ Million) in 2025 Figure 34. North America Poultry Live Attenuated Vaccine Revenue (US$ Million) by Application (2021-2032) Figure 35. US Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032 Figure 36. Canada Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032 Figure 37. Mexico Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032 Figure 38. Europe Poultry Live Attenuated Vaccine Revenue YoY (US$ Million), 2021-2032 Figure 39. Europe Top 5 Players Poultry Live Attenuated Vaccine Revenue (US$ Million) in 2025 Figure 40. Europe Poultry Live Attenuated Vaccine Revenue (US$ Million) by Application (2021-2032) Figure 41. Germany Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032 Figure 42. France Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032 Figure 43. U.K. Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032 Figure 44. Italy Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032 Figure 45. Russia Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032 Figure 46. Asia-Pacific Poultry Live Attenuated Vaccine Revenue YoY (US$ Million), 2021-2032 Figure 47. Asia-Pacific Top 8 Players Poultry Live Attenuated Vaccine Revenue (US$ Million) in 2025 Figure 48. Asia-Pacific Poultry Live Attenuated Vaccine Revenue (US$ Million) by Application (2021-2032) Figure 49. Indonesia Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032 Figure 50. Japan Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032 Figure 51. South Korea Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032 Figure 52. Australia Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032 Figure 53. India Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032 Figure 54. Indonesia Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032 Figure 55. Vietnam Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032 Figure 56. Malaysia Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032 Figure 57. Philippines Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032 Figure 58. Singapore Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032 Figure 59. Central and South America Poultry Live Attenuated Vaccine Revenue YoY (US$ Million), 2021-2032 Figure 60. Central and South America Top 5 Players Poultry Live Attenuated Vaccine Revenue (US$ Million) in 2025 Figure 61. Central and South America Poultry Live Attenuated Vaccine Revenue (US$ Million) by Application (2021-2032) Figure 62. Brazil Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032 Figure 63. Argentina Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032 Figure 64. Middle East and Africa Poultry Live Attenuated Vaccine Revenue YoY (US$ Million), 2021-2032 Figure 65. Middle East and Africa Top 5 Players Poultry Live Attenuated Vaccine Revenue (US$ Million) in 2025 Figure 66. Middle East and Africa Poultry Live Attenuated Vaccine Revenue (US$ Million) by Application (2021-2032) Figure 67. GCC Countries Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032 Figure 68. Israel Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032 Figure 69. Egypt Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032 Figure 70. South Africa Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032 Figure 71. Poultry Live Attenuated Vaccine Value Chain Mapping Figure 72. Channels of Distribution (Direct Vs Distribution) Figure 73. Bottom-up and Top-down Approaches for This Report Figure 74. Data Triangulation Figure 75. Key Executives Interviewed
SummaryThe global Poultry Live Attenuated Vaccine market is projected to grow from US$ 1209 million in 2025 to US$ 1623 million by 2032, at a CAGR of 4.5% (2026-2032), driven by critical product segments and diverse end‑use applications.Poultry Live Attenuated Vaccines are veterinary biological products containing live viruses, bacteria, or other microorganisms whose pathogenicity has been substantially reduced through serial passage, directed selection, genetic modification, or other attenuation techniques while retaining limited replication capacity and immunogenicity. They are used to prevent infectious diseases and establish vaccination programs in broilers, layers, breeders, and other poultry. By pathogen type, the product is classified into Live Attenuated Viral Vaccines, Live Attenuated Bacterial Vaccines, and Others; by Antigen Combination, into Monovalent, Bivalent, and Multivalent Live Attenuated Vaccines; and by Dosage Form, into Lyophilized, Frozen, and Liquid Live Attenuated Vaccines. Administration commonly includes spray, drinking water, eye/nose drop, subcutaneous injection, and in-ovo vaccination. Key parameters include dose per bird, EID50, TCID50, PFU or CFU potency, attenuation stability, genetic stability, onset and duration of immunity, maternal-antibody interference, and storage requirements. Key Findings The average industry gross margin in 2025 is approximately 45%–65%. Live Attenuated Viral Vaccines represent the largest segment, with lyophilized bivalent ND+IB vaccines being a representative high-volume product and typical potency of IB ≥10³ EID50/dose and ND ≥10⁶ EID50/dose. Broiler Farming represents the largest downstream application. MSD Animal Health, Zoetis, Boehringer Ingelheim, Ceva Santé Animale, and Elanco Animal Health are positioned among the leading global suppliers. Market Trends The product is evolving from conventional single-disease and repeated farm vaccination toward bivalent/multivalent combinations, centralized hatchery immunization, lower vaccine reactions, and longer-lasting protection. Lyophilized ND, IB, and IBD attenuated vaccines remain central to mass spray and drinking-water programs, while Frozen HVT-vector technologies are increasing their share of higher-value applications. Boehringer Ingelheim now offers HVT+IBD, HVT+IBD+ND, and HVT+IBD+ILT frozen live-vector combinations, while Ceva's HVT-vector technology expresses the NDV F protein to provide long-term protection. Future technology development will focus on reducing maternal-antibody interference, minimizing respiratory reactions, extending duration of immunity, and deeper integration with automated hatchery vaccination. Market Dynamics Drivers Demand for the product is primarily driven by high-density commercial poultry production, routine infectious-disease control, expansion of large hatcheries, and pressure to reduce vaccination cost per bird. Newcastle Disease and Infectious Bronchitis remain major diseases of commercial poultry; WOAH describes Newcastle Disease as globally widespread and Infectious Bronchitis as a major pathogen of commercial meat- and egg-type chickens. Live attenuated products can immunize thousands or tens of thousands of birds through spray or drinking water, making them especially suitable for short-cycle, high-throughput Broiler Farming. They can also stimulate humoral, local mucosal, and selected cellular immunity. Large poultry integrators increasingly use centralized hatchery spray, subcutaneous, or in-ovo administration to improve vaccination uniformity and reduce farm-level application errors. Restraints The main restraints include cold-chain sensitivity, variability in administration quality, maternal-antibody interference, and temporary reactions associated with selected attenuated strains. Lyophilized formulations must generally be used promptly after reconstitution, while chlorine or disinfectants in drinking water, spray droplet size, house temperature, and flock coverage can influence actual vaccination performance. Frozen HVT products require more demanding frozen or liquid-nitrogen logistics and hatchery handling. Certain conventional ND or IB attenuated strains may induce respiratory reactions under high-density, poorly ventilated, or secondary-infection conditions, meaning strain attenuation and vaccination timing must be matched to local disease pressure. WOAH also emphasizes that vaccination programs should consider vaccine type, flock immune status, disease status, and local field-virus infection risk. Opportunities Future opportunities are concentrated in Bivalent and Multivalent Live Attenuated Vaccines, single-dose hatchery immunization, Frozen live-vector technologies, and Live Attenuated Bacterial Vaccines. Bivalent ND+IB formulations provide protection against two major respiratory diseases in one administration. Zoetis offers relevant lyophilized products in 10,000-dose presentations for coarse spray or drinking-water use, demonstrating the importance of high-dose packaging and operational efficiency in mass vaccination. Frozen vector products provide a platform for integrating multiple protective antigens; Boehringer Ingelheim's HVT+IBD+ND can be administered to 18–19-day-old embryos or day-old chicks and is offered in 2,000- and 4,000-dose presentations. Live attenuated Salmonella products, region-specific strain combinations, and automated vaccination systems also provide future differentiation opportunities. Challenges The core challenge is maintaining attenuation safety, sufficient immunogenicity, and long-term genetic stability simultaneously. The organism must retain enough replication capacity to induce protective immunity, but insufficient attenuation can increase vaccine reactions or biosafety risks, while excessive attenuation may weaken protection. NDV and IBV also contain different genotypes or serotypes, and antigenic matching between vaccine and circulating field strains can influence protection and shedding control. WOAH requires attenuated live viruses to be produced under seed-lot systems with strict control over origin, purity, extraneous agents, and stability. Bivalent and Multivalent products add potential antigen interactions, increasing requirements for batch potency, vaccination scheduling, and field surveillance. Industry Chain Analysis The upstream supply chain mainly includes SPF embryonated chicken eggs, avian or other cell-culture substrates, master and working seed stocks, culture media, stabilizers, lyophilization protectants, sterile packaging, freeze dryers, bioreactors, filling equipment, and cold-chain infrastructure. Midstream activities include seed selection and attenuation, viral or bacterial propagation, harvesting, purification or clarification, potency determination, formulation, lyophilization/freezing/liquid filling, sterility testing, extraneous-agent testing, and batch release. WOAH states that attenuated IB virus is commonly propagated in the allantoic cavity of SPF embryonated chicken eggs or suitable cell cultures and that live vaccine harvest can be formulated into lyophilized or frozen presentations. Downstream demand includes Broiler Farming, Layer Farming, Breeder Farming, and Other poultry operations, together with hatcheries, veterinary distribution, spray equipment, drinking-water systems, in-ovo injectors, and frozen or liquid-nitrogen logistics. Leading suppliers also provide vaccination-program design, administration-quality auditing, and serological monitoring. Segment Insights By pathogen type, Live Attenuated Viral Vaccines represent the largest segment and primarily cover ND, IB, IBD, Marek's Disease, and other viral diseases, with lyophilized ND/IB vaccines representing one of the most mature commercial combinations. Zoetis' B1+Conn/Mass and LaSota+Mass products combine attenuated NDV and IBV, are offered in packages of up to 10 × 10,000 doses, and are administered through drinking water or coarse spray; WOAH confirms that live IBV can be formulated in lyophilized or frozen forms. Live Attenuated Bacterial Vaccines mainly address pathogens such as Salmonella and account for a smaller market share but offer increasing value in food-safety programs and enteric disease control in layers and breeders. By Antigen Combination and Dosage Form, Monovalent products allow flexible targeting of individual diseases or regional strains, Bivalent products are most clearly represented by ND+IB combinations, and Multivalent products are increasingly enabled by vector platforms. Lyophilized formulations remain the mainstream conventional format because of mature transport, packaging, and mass-administration systems. Frozen formulations are concentrated in higher-value HVT, Marek's, and recombinant-vector applications; Boehringer Ingelheim explicitly lists both Frozen and Frozen Vector products administered subcutaneously or in ovo. Liquid products are used in selected bacterial and ready-to-use applications. Technology is therefore moving from repeated farm use of lyophilized Monovalent/Bivalent vaccines toward precise hatchery priming with Frozen Multivalent platforms plus risk-based field boosting. Downstream Market Opportunities Broiler Farming represents the largest application because flock sizes are large, production cycles are short, and early protection against ND, IB, IBD, and Marek's Disease must be established at very low cost per bird, making spray, drinking-water, and hatchery vaccination highly suitable. Layer Farming has a longer production cycle and places greater emphasis on long-duration protection and scheduled boosters, while Breeder Farming must protect the parent flock while also supporting stable maternal-antibody transfer to progeny. Boehringer Ingelheim's HVT+IBD+ND is specifically indicated for broilers, commercial layers, and breeders. Artificial intelligence is not part of the vaccine itself, but it can combine mortality, antibody titers, production performance, house-environment parameters, and regional outbreak data to optimize priming age and booster intervals and can use machine vision to monitor hatchery spray coverage and missed vaccination. Regional Insights Asia-Pacific is an important production and consumption region with large Broiler, Layer, and Breeder industries and substantial demand for control of ND, IB, and IBD. Market participants include QYH Biotech, Pulike, Harbin Pharmaceutical Group, Nisseiken, Hester Biosciences, Phibro Animal Health, Vaxxinova, KBNP, Jilin Zhengye, Yebio, Sinder, and Guangzhou South China Biological Medicine. North America has highly integrated hatchery and poultry-production systems, supporting mature markets for large-dose Lyophilized vaccines and automated administration. Europe has a strong technology base in recombinant vectors, hatchery immunization, and quality regulation. WOAH describes Newcastle Disease as globally widespread and Infectious Bronchitis as a worldwide disease of commercial chickens, sustaining long-term demand for cost-efficient conventional Lyophilized attenuated vaccines in Asia, Africa, and Latin America. Competitive Landscape Analysis The product has substantial barriers in seed technology, SPF production systems, biological manufacturing facilities, quality control, cold-chain management, and regulatory approval. Representative leading players include MSD Animal Health (Merck), Zoetis, Boehringer Ingelheim, Ceva Santé Animale, and Elanco Animal Health. Boehringer Ingelheim's portfolio spans conventional Lyophilized IBD live vaccines, Frozen Marek's vaccines, and HVT+IBD and HVT+IBD+ND live-vector platforms. Zoetis uses established B1, LaSota, Massachusetts, and Connecticut strains across ND, IB, and combination modified-live portfolios, while Ceva combines HVT-vector technology with conventional day-one attenuated ND vaccination in integrated control programs. Competition among leading suppliers is shifting from individual strains and potency toward broader antigen combinations, Frozen vector platforms, hatchery automation, maternal-antibody compatibility, and complete vaccination-program services. Report Scope This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Poultry Live Attenuated Vaccine market across value chain. It analyzes historical revenue data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers. By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern. Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends. Critical competitive intelligence profiles players (revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths. A concise Industry‑chain overview maps upstream, middle stream, and downstream distribution dynamics to identify strategic gaps and unmet demand. Market Segmentation By Company MSD Animal Health(Merck) Zoetis Boehringer Ingelheim Ceva Santé Animale Elanco Animal Health HIPRA Vaxxinova QYH Biotech Pulike Harbin Pharmaceutical Group Nisseiken Hester Biosciences Phibro Animal Health CAVAC KBNP Bioveta Jilin Zhengye Yebio Sinder Guangzhou South China Biological Medicine Segment by Type Live Attenuated Viral Vaccines Live Attenuated Bacterial Vaccines Others Segment by Antigen Combination Monovalent Live Attenuated Vaccines Bivalent Live Attenuated Vaccines Multivalent Live Attenuated Vaccines Segment by Dosage Form Lyophilized Live Attenuated Vaccines Frozen Live Attenuated Vaccines Liquid Live Attenuated Vaccines Segment by Application Broiler Farming Layer Farming Breeder Farming Others Segment by Region North America United States Canada Mexico Asia-Pacific China Japan South Korea India Australia Vietnam Indonesia Malaysia Philippines Singapore Rest of Asia Europe Germany U.K. France Italy Spain Benelux Russia Rest of Europe Central and South America Brazil Argentina Rest of Central and South America Middle East & Africa GCC Countries Egypt Israel South Africa Rest of MEA Chapter Outline Chapter 1: Defines the Poultry Live Attenuated Vaccine study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts Chapter 3: Dissects the player landscape: ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves Chapter 4: Unlocks high margin product segments: compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks Chapter 5: Targets downstream market opportunities: evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application Chapter 6: North America: breaks down market size by Application and country, profiles key players and assesses growth drivers and barriers Chapter 7: Europe: analyses regional market by Application and players, flagging drivers and barriers Chapter 8: Asia Pacific: quantifies market size by Application, and region/country, profiles top players, and uncovers high potential expansion areas Chapter 9: Central & South America: measures market size by Application, and country, profiles top players, and identifies investment opportunities and challenges Chapter 10: Middle East and Africa: evaluates market size by Application, and country, profiles key players, and outlines investment prospects and market hurdles Chapter 11: Profiles players in depth: details product specs, revenue, margins; top-tier players 2025 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments Chapter 12: Value chain and ecosystem: analyses upstream, midstream, plus downstream channels Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies Chapter 14: Actionable conclusions and strategic recommendations. Why This Report Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to: Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5). Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence. Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11). Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14). Leverage this 360° intelligence to turn market complexity into actionable competitive advantage. Table of Contents1 Study Coverage1.1 Introduction to Poultry Live Attenuated Vaccine: Definition, Properties, and Key Attributes 1.2 Market Segmentation by Type 1.2.1 Global Poultry Live Attenuated Vaccine Market Size by Type, 2021 vs 2025 vs 2032 1.2.2 Live Attenuated Viral Vaccines 1.2.3 Live Attenuated Bacterial Vaccines 1.2.4 Others 1.3 Market Segmentation by Antigen Combination 1.3.1 Global Poultry Live Attenuated Vaccine Market Size by Antigen Combination, 2021 vs 2025 vs 2032 1.3.2 Monovalent Live Attenuated Vaccines 1.3.3 Bivalent Live Attenuated Vaccines 1.3.4 Multivalent Live Attenuated Vaccines 1.4 Market Segmentation by Dosage Form 1.4.1 Global Poultry Live Attenuated Vaccine Market Size by Dosage Form, 2021 vs 2025 vs 2032 1.4.2 Lyophilized Live Attenuated Vaccines 1.4.3 Frozen Live Attenuated Vaccines 1.4.4 Liquid Live Attenuated Vaccines 1.5 Market Segmentation by Application 1.5.1 Global Poultry Live Attenuated Vaccine Market Size by Application, 2021 vs 2025 vs 2032 1.5.2 Broiler Farming 1.5.3 Layer Farming 1.5.4 Breeder Farming 1.5.5 Others 1.6 Assumptions and Limitations 1.7 Study Objectives 1.8 Years Considered 2 Executive Summary 2.1 Global Poultry Live Attenuated Vaccine Revenue Estimates and Forecasts (2021-2032) 2.2 Global Poultry Live Attenuated Vaccine Revenue by Region 2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032 2.2.2 Historical and Forecasted Revenue by Region (2021-2032) 2.2.3 Global Revenue-Based Market Share by Region (2021-2032) 2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends 3 Competitive Landscape 3.1 Global Poultry Live Attenuated Vaccine Players’ Revenue Rankings and Profitability 3.1.1 Global Revenue (Value) by Players (2021-2026) 3.1.2 Global Key Players’ Revenue Ranking (2024 vs 2025) 3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3) 3.1.4 Gross Margin by Top Players (2021 vs 2025) 3.2 Global Poultry Live Attenuated Vaccine Companies Headquarters and Service Footprint 3.3 Key Player Market Share by Product Type 3.3.1 Live Attenuated Viral Vaccines: Market Share by Key Players 3.3.2 Live Attenuated Bacterial Vaccines: Market Share by Key Players 3.3.3 Others: Market Share by Key Players 3.4 Global Poultry Live Attenuated Vaccine Market Concentration and Dynamics 3.4.1 Global Market Concentration 3.4.2 Market Entry and Exit Analysis 3.4.3 Strategic Moves: M&A, Expansion, R&D Investment 4 Product Segmentation 4.1 Global Poultry Live Attenuated Vaccine Market by Type 4.1.1 Global Revenue by Type (2021-2032) 4.1.2 Global Revenue-Based Market Share by Type (2021-2032) 4.2 Global Poultry Live Attenuated Vaccine Market by Antigen Combination 4.2.1 Global Revenue by Antigen Combination (2021-2032) 4.2.2 Global Revenue-Based Market Share by Antigen Combination (2021-2032) 4.3 Global Poultry Live Attenuated Vaccine Market by Dosage Form 4.3.1 Global Revenue by Dosage Form (2021-2032) 4.3.2 Global Revenue-Based Market Share by Dosage Form (2021-2032) 4.4 Key Product Attributes and Differentiation 4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk 4.5.1 High-Growth Niches and Adoption Drivers 4.5.2 Profitability Hotspots and Cost Drivers 4.5.3 Substitution Threats 5 Downstream Applications and Customers 5.1 Global Poultry Live Attenuated Vaccine Revenue by Application 5.1.1 Global Historical and Forecasted Revenue by Application (2021-2032) 5.1.2 Revenue-Based Market Share by Application (2021-2032) 5.1.3 High-Growth Application Identification 5.1.4 Emerging Application Case Studies 5.2 Downstream Customer Analysis 5.2.1 Top Customers by Region 5.2.2 Top Customers by Application 6 North America 6.1 North America Market Size (2021-2032) 6.2 North America Key Players’ Revenue in 2025 6.3 North America Poultry Live Attenuated Vaccine Market Size by Application (2021-2032) 6.4 North America Growth Accelerators and Market Barriers 6.5 North America Poultry Live Attenuated Vaccine Market Size by Country 6.5.1 North America Revenue Trends by Country 6.5.2 US 6.5.3 Canada 6.5.4 Mexico 7 Europe 7.1 Europe Market Size (2021-2032) 7.2 Europe Key Players’ Revenue in 2025 7.3 Europe Poultry Live Attenuated Vaccine Market Size by Application (2021-2032) 7.4 Europe Growth Accelerators and Market Barriers 7.5 Europe Poultry Live Attenuated Vaccine Market Size by Country 7.5.1 Europe Revenue Trends by Country 7.5.2 Germany 7.5.3 France 7.5.4 U.K. 7.5.5 Italy 7.5.6 Russia 8 Asia-Pacific 8.1 Asia-Pacific Market Size (2021-2032) 8.2 Asia-Pacific Key Players’ Revenue in 2025 8.3 Asia-Pacific Poultry Live Attenuated Vaccine Market Size by Application (2021-2032) 8.4 Asia-Pacific Growth Accelerators and Market Barriers 8.5 Asia-Pacific Poultry Live Attenuated Vaccine Market Size by Region 8.5.1 Asia-Pacific Revenue Trends by Region 8.6 China 8.7 Japan 8.8 South Korea 8.9 Australia 8.10 India 8.11 Southeast Asia 8.11.1 Indonesia 8.11.2 Vietnam 8.11.3 Malaysia 8.11.4 Philippines 8.11.5 Singapore 9 Central and South America 9.1 Central and South America Market Size (2021-2032) 9.2 Central and South America Key Players’ Revenue in 2025 9.3 Central and South America Poultry Live Attenuated Vaccine Market Size by Application (2021-2032) 9.4 Central and South America Investment Opportunities and Key Challenges 9.5 Central and South America Poultry Live Attenuated Vaccine Market Size by Country 9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032) 9.5.2 Brazil 9.5.3 Argentina 10 Middle East and Africa 10.1 Middle East and Africa Market Size (2021-2032) 10.2 Middle East and Africa Key Players’ Revenue in 2025 10.3 Middle East and Africa Poultry Live Attenuated Vaccine Market Size by Application (2021-2032) 10.4 Middle East and Africa Investment Opportunities and Key Challenges 10.5 Middle East and Africa Poultry Live Attenuated Vaccine Market Size by Country 10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032) 10.5.2 GCC Countries 10.5.3 Israel 10.5.4 Egypt 10.5.5 South Africa 11 Corporate Profile 11.1 MSD Animal Health(Merck) 11.1.1 MSD Animal Health(Merck) Corporation Information 11.1.2 MSD Animal Health(Merck) Business Overview 11.1.3 MSD Animal Health(Merck) Poultry Live Attenuated Vaccine Product Features and Attributes 11.1.4 MSD Animal Health(Merck) Poultry Live Attenuated Vaccine Revenue and Gross Margin (2021-2026) 11.1.5 MSD Animal Health(Merck) Poultry Live Attenuated Vaccine Revenue by Product in 2025 11.1.6 MSD Animal Health(Merck) Poultry Live Attenuated Vaccine Revenue by Application in 2025 11.1.7 MSD Animal Health(Merck) Poultry Live Attenuated Vaccine Revenue by Geographic Area in 2025 11.1.8 MSD Animal Health(Merck) Poultry Live Attenuated Vaccine SWOT Analysis 11.1.9 MSD Animal Health(Merck) Recent Developments 11.2 Zoetis 11.2.1 Zoetis Corporation Information 11.2.2 Zoetis Business Overview 11.2.3 Zoetis Poultry Live Attenuated Vaccine Product Features and Attributes 11.2.4 Zoetis Poultry Live Attenuated Vaccine Revenue and Gross Margin (2021-2026) 11.2.5 Zoetis Poultry Live Attenuated Vaccine Revenue by Product in 2025 11.2.6 Zoetis Poultry Live Attenuated Vaccine Revenue by Application in 2025 11.2.7 Zoetis Poultry Live Attenuated Vaccine Revenue by Geographic Area in 2025 11.2.8 Zoetis Poultry Live Attenuated Vaccine SWOT Analysis 11.2.9 Zoetis Recent Developments 11.3 Boehringer Ingelheim 11.3.1 Boehringer Ingelheim Corporation Information 11.3.2 Boehringer Ingelheim Business Overview 11.3.3 Boehringer Ingelheim Poultry Live Attenuated Vaccine Product Features and Attributes 11.3.4 Boehringer Ingelheim Poultry Live Attenuated Vaccine Revenue and Gross Margin (2021-2026) 11.3.5 Boehringer Ingelheim Poultry Live Attenuated Vaccine Revenue by Product in 2025 11.3.6 Boehringer Ingelheim Poultry Live Attenuated Vaccine Revenue by Application in 2025 11.3.7 Boehringer Ingelheim Poultry Live Attenuated Vaccine Revenue by Geographic Area in 2025 11.3.8 Boehringer Ingelheim Poultry Live Attenuated Vaccine SWOT Analysis 11.3.9 Boehringer Ingelheim Recent Developments 11.4 Ceva Santé Animale 11.4.1 Ceva Santé Animale Corporation Information 11.4.2 Ceva Santé Animale Business Overview 11.4.3 Ceva Santé Animale Poultry Live Attenuated Vaccine Product Features and Attributes 11.4.4 Ceva Santé Animale Poultry Live Attenuated Vaccine Revenue and Gross Margin (2021-2026) 11.4.5 Ceva Santé Animale Poultry Live Attenuated Vaccine Revenue by Product in 2025 11.4.6 Ceva Santé Animale Poultry Live Attenuated Vaccine Revenue by Application in 2025 11.4.7 Ceva Santé Animale Poultry Live Attenuated Vaccine Revenue by Geographic Area in 2025 11.4.8 Ceva Santé Animale Poultry Live Attenuated Vaccine SWOT Analysis 11.4.9 Ceva Santé Animale Recent Developments 11.5 Elanco Animal Health 11.5.1 Elanco Animal Health Corporation Information 11.5.2 Elanco Animal Health Business Overview 11.5.3 Elanco Animal Health Poultry Live Attenuated Vaccine Product Features and Attributes 11.5.4 Elanco Animal Health Poultry Live Attenuated Vaccine Revenue and Gross Margin (2021-2026) 11.5.5 Elanco Animal Health Poultry Live Attenuated Vaccine Revenue by Product in 2025 11.5.6 Elanco Animal Health Poultry Live Attenuated Vaccine Revenue by Application in 2025 11.5.7 Elanco Animal Health Poultry Live Attenuated Vaccine Revenue by Geographic Area in 2025 11.5.8 Elanco Animal Health Poultry Live Attenuated Vaccine SWOT Analysis 11.5.9 Elanco Animal Health Recent Developments 11.6 HIPRA 11.6.1 HIPRA Corporation Information 11.6.2 HIPRA Business Overview 11.6.3 HIPRA Poultry Live Attenuated Vaccine Product Features and Attributes 11.6.4 HIPRA Poultry Live Attenuated Vaccine Revenue and Gross Margin (2021-2026) 11.6.5 HIPRA Recent Developments 11.7 Vaxxinova 11.7.1 Vaxxinova Corporation Information 11.7.2 Vaxxinova Business Overview 11.7.3 Vaxxinova Poultry Live Attenuated Vaccine Product Features and Attributes 11.7.4 Vaxxinova Poultry Live Attenuated Vaccine Revenue and Gross Margin (2021-2026) 11.7.5 Vaxxinova Recent Developments 11.8 QYH Biotech 11.8.1 QYH Biotech Corporation Information 11.8.2 QYH Biotech Business Overview 11.8.3 QYH Biotech Poultry Live Attenuated Vaccine Product Features and Attributes 11.8.4 QYH Biotech Poultry Live Attenuated Vaccine Revenue and Gross Margin (2021-2026) 11.8.5 QYH Biotech Recent Developments 11.9 Pulike 11.9.1 Pulike Corporation Information 11.9.2 Pulike Business Overview 11.9.3 Pulike Poultry Live Attenuated Vaccine Product Features and Attributes 11.9.4 Pulike Poultry Live Attenuated Vaccine Revenue and Gross Margin (2021-2026) 11.9.5 Pulike Recent Developments 11.10 Harbin Pharmaceutical Group 11.10.1 Harbin Pharmaceutical Group Corporation Information 11.10.2 Harbin Pharmaceutical Group Business Overview 11.10.3 Harbin Pharmaceutical Group Poultry Live Attenuated Vaccine Product Features and Attributes 11.10.4 Harbin Pharmaceutical Group Poultry Live Attenuated Vaccine Revenue and Gross Margin (2021-2026) 11.10.5 Company Ten Recent Developments 11.11 Nisseiken 11.11.1 Nisseiken Corporation Information 11.11.2 Nisseiken Business Overview 11.11.3 Nisseiken Poultry Live Attenuated Vaccine Product Features and Attributes 11.11.4 Nisseiken Poultry Live Attenuated Vaccine Revenue and Gross Margin (2021-2026) 11.11.5 Nisseiken Recent Developments 11.12 Hester Biosciences 11.12.1 Hester Biosciences Corporation Information 11.12.2 Hester Biosciences Business Overview 11.12.3 Hester Biosciences Poultry Live Attenuated Vaccine Product Features and Attributes 11.12.4 Hester Biosciences Poultry Live Attenuated Vaccine Revenue and Gross Margin (2021-2026) 11.12.5 Hester Biosciences Recent Developments 11.13 Phibro Animal Health 11.13.1 Phibro Animal Health Corporation Information 11.13.2 Phibro Animal Health Business Overview 11.13.3 Phibro Animal Health Poultry Live Attenuated Vaccine Product Features and Attributes 11.13.4 Phibro Animal Health Poultry Live Attenuated Vaccine Revenue and Gross Margin (2021-2026) 11.13.5 Phibro Animal Health Recent Developments 11.14 CAVAC 11.14.1 CAVAC Corporation Information 11.14.2 CAVAC Business Overview 11.14.3 CAVAC Poultry Live Attenuated Vaccine Product Features and Attributes 11.14.4 CAVAC Poultry Live Attenuated Vaccine Revenue and Gross Margin (2021-2026) 11.14.5 CAVAC Recent Developments 11.15 KBNP 11.15.1 KBNP Corporation Information 11.15.2 KBNP Business Overview 11.15.3 KBNP Poultry Live Attenuated Vaccine Product Features and Attributes 11.15.4 KBNP Poultry Live Attenuated Vaccine Revenue and Gross Margin (2021-2026) 11.15.5 KBNP Recent Developments 11.16 Bioveta 11.16.1 Bioveta Corporation Information 11.16.2 Bioveta Business Overview 11.16.3 Bioveta Poultry Live Attenuated Vaccine Product Features and Attributes 11.16.4 Bioveta Poultry Live Attenuated Vaccine Revenue and Gross Margin (2021-2026) 11.16.5 Bioveta Recent Developments 11.17 Jilin Zhengye 11.17.1 Jilin Zhengye Corporation Information 11.17.2 Jilin Zhengye Business Overview 11.17.3 Jilin Zhengye Poultry Live Attenuated Vaccine Product Features and Attributes 11.17.4 Jilin Zhengye Poultry Live Attenuated Vaccine Revenue and Gross Margin (2021-2026) 11.17.5 Jilin Zhengye Recent Developments 11.18 Yebio 11.18.1 Yebio Corporation Information 11.18.2 Yebio Business Overview 11.18.3 Yebio Poultry Live Attenuated Vaccine Product Features and Attributes 11.18.4 Yebio Poultry Live Attenuated Vaccine Revenue and Gross Margin (2021-2026) 11.18.5 Yebio Recent Developments 11.19 Sinder 11.19.1 Sinder Corporation Information 11.19.2 Sinder Business Overview 11.19.3 Sinder Poultry Live Attenuated Vaccine Product Features and Attributes 11.19.4 Sinder Poultry Live Attenuated Vaccine Revenue and Gross Margin (2021-2026) 11.19.5 Sinder Recent Developments 11.20 Guangzhou South China Biological Medicine 11.20.1 Guangzhou South China Biological Medicine Corporation Information 11.20.2 Guangzhou South China Biological Medicine Business Overview 11.20.3 Guangzhou South China Biological Medicine Poultry Live Attenuated Vaccine Product Features and Attributes 11.20.4 Guangzhou South China Biological Medicine Poultry Live Attenuated Vaccine Revenue and Gross Margin (2021-2026) 11.20.5 Guangzhou South China Biological Medicine Recent Developments 12 Poultry Live Attenuated Vaccine Value Chain and Ecosystem Analysis 12.1 Poultry Live Attenuated Vaccine Value Chain (Ecosystem Structure) 12.2 Upstream Analysis 12.2.1 Key Technologies, Platforms and Infrastructure 12.3 Midstream Analysis 12.4 Downstream Sales Model and Distribution Networks 12.4.1 Sales Channels 12.4.2 Distributors 13 Poultry Live Attenuated Vaccine Market Dynamics 13.1 Industry Trends and Evolution 13.2 Market Growth Drivers and Emerging Opportunities 13.3 Market Challenges, Risks, and Restraints 14 Key Findings in the Global Poultry Live Attenuated Vaccine Study 15 Appendix 15.1 Research Methodology 15.1.1 Methodology/Research Approach 15.1.1.1 Research Programs/Design 15.1.1.2 Market Size Estimation 15.1.1.3 Market Breakdown and Data Triangulation 15.1.2 Data Source 15.1.2.1 Secondary Sources 15.1.2.2 Primary Sources 15.2 Author Details List of Tables/GraphsList of TablesTable 1. Global Poultry Live Attenuated Vaccine Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million) Table 2. Global Poultry Live Attenuated Vaccine Market Size Growth Rate by Antigen Combination, 2021 vs 2025 vs 2032 (US$ Million) Table 3. Global Poultry Live Attenuated Vaccine Market Size Growth Rate by Dosage Form, 2021 vs 2025 vs 2032 (US$ Million) Table 4. Global Poultry Live Attenuated Vaccine Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million) Table 5. Global Poultry Live Attenuated Vaccine Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million) Table 6. Global Poultry Live Attenuated Vaccine Revenue by Region (US$ Million), 2021-2026 Table 7. Global Poultry Live Attenuated Vaccine Revenue by Region (US$ Million), 2027-2032 Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million) Table 9. Global Poultry Live Attenuated Vaccine Revenue by Players (US$ Million), 2021-2026 Table 10. Global Poultry Live Attenuated Vaccine Revenue-Based Market Share by Players (2021-2026) Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue) Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Poultry Live Attenuated Vaccine Revenue, 2025 Table 13. Global Poultry Live Attenuated Vaccine Average Gross Margin (%) by Player (2021 vs 2025) Table 14. Global Poultry Live Attenuated Vaccine Companies Headquarters Table 15. Global Poultry Live Attenuated Vaccine Market Concentration Ratio (CR5) Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment Table 18. Global Poultry Live Attenuated Vaccine Revenue by Type (US$ Million), 2021-2026 Table 19. Global Poultry Live Attenuated Vaccine Revenue by Type (US$ Million), 2027-2032 Table 20. Global Poultry Live Attenuated Vaccine Revenue by Antigen Combination (US$ Million), 2021-2026 Table 21. Global Poultry Live Attenuated Vaccine Revenue by Antigen Combination (US$ Million), 2027-2032 Table 22. Global Poultry Live Attenuated Vaccine Revenue by Dosage Form (US$ Million), 2021-2026 Table 23. Global Poultry Live Attenuated Vaccine Revenue by Dosage Form (US$ Million), 2027-2032 Table 24. Key Product Attributes and Differentiation Table 25. Global Poultry Live Attenuated Vaccine Revenue by Application (US$ Million), 2021-2026 Table 26. Global Poultry Live Attenuated Vaccine Revenue by Application (US$ Million), 2027-2032 Table 27. Poultry Live Attenuated Vaccine High-Growth Sectors Demand CAGR (2026-2032) Table 28. Top Customers by Region Table 29. Top Customers by Application Table 30. North America Poultry Live Attenuated Vaccine Growth Accelerators and Market Barriers Table 31. North America Poultry Live Attenuated Vaccine Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million) Table 32. Europe Poultry Live Attenuated Vaccine Growth Accelerators and Market Barriers Table 33. Europe Poultry Live Attenuated Vaccine Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million) Table 34. Asia-Pacific Poultry Live Attenuated Vaccine Growth Accelerators and Market Barriers Table 35. Asia-Pacific Poultry Live Attenuated Vaccine Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million) Table 36. Central and South America Poultry Live Attenuated Vaccine Investment Opportunities and Key Challenges Table 37. Central and South America Poultry Live Attenuated Vaccine Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million) Table 38. Middle East and Africa Poultry Live Attenuated Vaccine Investment Opportunities and Key Challenges Table 39. Middle East and Africa Poultry Live Attenuated Vaccine Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million) Table 40. MSD Animal Health(Merck) Corporation Information Table 41. MSD Animal Health(Merck) Description and Major Businesses Table 42. MSD Animal Health(Merck) Product Features and Attributes Table 43. MSD Animal Health(Merck) Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. MSD Animal Health(Merck) Revenue Proportion by Product in 2025 Table 45. MSD Animal Health(Merck) Revenue Proportion by Application in 2025 Table 46. MSD Animal Health(Merck) Revenue Proportion by Geographic Area in 2025 Table 47. MSD Animal Health(Merck) Poultry Live Attenuated Vaccine SWOT Analysis Table 48. MSD Animal Health(Merck) Recent Developments Table 49. Zoetis Corporation Information Table 50. Zoetis Description and Major Businesses Table 51. Zoetis Product Features and Attributes Table 52. Zoetis Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Zoetis Revenue Proportion by Product in 2025 Table 54. Zoetis Revenue Proportion by Application in 2025 Table 55. Zoetis Revenue Proportion by Geographic Area in 2025 Table 56. Zoetis Poultry Live Attenuated Vaccine SWOT Analysis Table 57. Zoetis Recent Developments Table 58. Boehringer Ingelheim Corporation Information Table 59. Boehringer Ingelheim Description and Major Businesses Table 60. Boehringer Ingelheim Product Features and Attributes Table 61. Boehringer Ingelheim Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Boehringer Ingelheim Revenue Proportion by Product in 2025 Table 63. Boehringer Ingelheim Revenue Proportion by Application in 2025 Table 64. Boehringer Ingelheim Revenue Proportion by Geographic Area in 2025 Table 65. Boehringer Ingelheim Poultry Live Attenuated Vaccine SWOT Analysis Table 66. Boehringer Ingelheim Recent Developments Table 67. Ceva Santé Animale Corporation Information Table 68. Ceva Santé Animale Description and Major Businesses Table 69. Ceva Santé Animale Product Features and Attributes Table 70. Ceva Santé Animale Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Ceva Santé Animale Revenue Proportion by Product in 2025 Table 72. Ceva Santé Animale Revenue Proportion by Application in 2025 Table 73. Ceva Santé Animale Revenue Proportion by Geographic Area in 2025 Table 74. Ceva Santé Animale Poultry Live Attenuated Vaccine SWOT Analysis Table 75. Ceva Santé Animale Recent Developments Table 76. Elanco Animal Health Corporation Information Table 77. Elanco Animal Health Description and Major Businesses Table 78. Elanco Animal Health Product Features and Attributes Table 79. Elanco Animal Health Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Elanco Animal Health Revenue Proportion by Product in 2025 Table 81. Elanco Animal Health Revenue Proportion by Application in 2025 Table 82. Elanco Animal Health Revenue Proportion by Geographic Area in 2025 Table 83. Elanco Animal Health Poultry Live Attenuated Vaccine SWOT Analysis Table 84. Elanco Animal Health Recent Developments Table 85. HIPRA Corporation Information Table 86. HIPRA Description and Major Businesses Table 87. HIPRA Product Features and Attributes Table 88. HIPRA Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. HIPRA Recent Developments Table 90. Vaxxinova Corporation Information Table 91. Vaxxinova Description and Major Businesses Table 92. Vaxxinova Product Features and Attributes Table 93. Vaxxinova Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Vaxxinova Recent Developments Table 95. QYH Biotech Corporation Information Table 96. QYH Biotech Description and Major Businesses Table 97. QYH Biotech Product Features and Attributes Table 98. QYH Biotech Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. QYH Biotech Recent Developments Table 100. Pulike Corporation Information Table 101. Pulike Description and Major Businesses Table 102. Pulike Product Features and Attributes Table 103. Pulike Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. Pulike Recent Developments Table 105. Harbin Pharmaceutical Group Corporation Information Table 106. Harbin Pharmaceutical Group Description and Major Businesses Table 107. Harbin Pharmaceutical Group Product Features and Attributes Table 108. Harbin Pharmaceutical Group Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. Harbin Pharmaceutical Group Recent Developments Table 110. Nisseiken Corporation Information Table 111. Nisseiken Description and Major Businesses Table 112. Nisseiken Product Features and Attributes Table 113. Nisseiken Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. Nisseiken Recent Developments Table 115. Hester Biosciences Corporation Information Table 116. Hester Biosciences Description and Major Businesses Table 117. Hester Biosciences Product Features and Attributes Table 118. Hester Biosciences Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. Hester Biosciences Recent Developments Table 120. Phibro Animal Health Corporation Information Table 121. Phibro Animal Health Description and Major Businesses Table 122. Phibro Animal Health Product Features and Attributes Table 123. Phibro Animal Health Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. Phibro Animal Health Recent Developments Table 125. CAVAC Corporation Information Table 126. CAVAC Description and Major Businesses Table 127. CAVAC Product Features and Attributes Table 128. CAVAC Revenue (US$ Million) and Gross Margin (2021-2026) Table 129. CAVAC Recent Developments Table 130. KBNP Corporation Information Table 131. KBNP Description and Major Businesses Table 132. KBNP Product Features and Attributes Table 133. KBNP Revenue (US$ Million) and Gross Margin (2021-2026) Table 134. KBNP Recent Developments Table 135. Bioveta Corporation Information Table 136. Bioveta Description and Major Businesses Table 137. Bioveta Product Features and Attributes Table 138. Bioveta Revenue (US$ Million) and Gross Margin (2021-2026) Table 139. Bioveta Recent Developments Table 140. Jilin Zhengye Corporation Information Table 141. Jilin Zhengye Description and Major Businesses Table 142. Jilin Zhengye Product Features and Attributes Table 143. Jilin Zhengye Revenue (US$ Million) and Gross Margin (2021-2026) Table 144. Jilin Zhengye Recent Developments Table 145. Yebio Corporation Information Table 146. Yebio Description and Major Businesses Table 147. Yebio Product Features and Attributes Table 148. Yebio Revenue (US$ Million) and Gross Margin (2021-2026) Table 149. Yebio Recent Developments Table 150. Sinder Corporation Information Table 151. Sinder Description and Major Businesses Table 152. Sinder Product Features and Attributes Table 153. Sinder Revenue (US$ Million) and Gross Margin (2021-2026) Table 154. Sinder Recent Developments Table 155. Guangzhou South China Biological Medicine Corporation Information Table 156. Guangzhou South China Biological Medicine Description and Major Businesses Table 157. Guangzhou South China Biological Medicine Product Features and Attributes Table 158. Guangzhou South China Biological Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 159. Guangzhou South China Biological Medicine Recent Developments Table 160. Technologies, Platforms and Infrastructure Table 161. Distributors List Table 162. Market Trends and Market Evolution Table 163. Market Drivers and Opportunities Table 164. Market Challenges, Risks, and Restraints Table 165. Research Programs/Design for This Report Table 166. Key Data Information from Secondary Sources Table 167. Key Data Information from Primary Sources List of Figures Figure 1. Global Poultry Live Attenuated Vaccine Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million) Figure 2. Live Attenuated Viral Vaccines Product Picture Figure 3. Live Attenuated Bacterial Vaccines Product Picture Figure 4. Others Product Picture Figure 5. Global Poultry Live Attenuated Vaccine Market Size Growth Rate by Antigen Combination, 2021 vs 2025 vs 2032 (US$ Million) Figure 6. Monovalent Live Attenuated Vaccines Product Picture Figure 7. Bivalent Live Attenuated Vaccines Product Picture Figure 8. Multivalent Live Attenuated Vaccines Product Picture Figure 9. Global Poultry Live Attenuated Vaccine Market Size Growth Rate by Dosage Form, 2021 vs 2025 vs 2032 (US$ Million) Figure 10. Lyophilized Live Attenuated Vaccines Product Picture Figure 11. Frozen Live Attenuated Vaccines Product Picture Figure 12. Liquid Live Attenuated Vaccines Product Picture Figure 13. Global Poultry Live Attenuated Vaccine Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million) Figure 14. Broiler Farming Figure 15. Layer Farming Figure 16. Breeder Farming Figure 17. Others Figure 18. Poultry Live Attenuated Vaccine Report Years Considered Figure 19. Global Poultry Live Attenuated Vaccine Revenue, (US$ Million), 2021 vs 2025 vs 2032 Figure 20. Global Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032 Figure 21. Global Poultry Live Attenuated Vaccine Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million) Figure 22. Global Poultry Live Attenuated Vaccine Revenue-Based Market Share by Region (2021-2032) Figure 23. Global Poultry Live Attenuated Vaccine Revenue-Based Market Share Ranking (2025) Figure 24. Tier Distribution by Revenue Contribution (2021 vs 2025) Figure 25. Live Attenuated Viral Vaccines Revenue-Based Market Share by Player in 2025 Figure 26. Live Attenuated Bacterial Vaccines Revenue-Based Market Share by Player in 2025 Figure 27. Others Revenue-Based Market Share by Player in 2025 Figure 28. Global Poultry Live Attenuated Vaccine Revenue-Based Market Share by Type (2021-2032) Figure 29. Global Poultry Live Attenuated Vaccine Revenue-Based Market Share by Antigen Combination (2021-2032) Figure 30. Global Poultry Live Attenuated Vaccine Revenue-Based Market Share by Dosage Form (2021-2032) Figure 31. Global Poultry Live Attenuated Vaccine Revenue-Based Market Share by Application (2021-2032) Figure 32. North America Poultry Live Attenuated Vaccine Revenue YoY (US$ Million), 2021-2032 Figure 33. North America Top 5 Players Poultry Live Attenuated Vaccine Revenue (US$ Million) in 2025 Figure 34. North America Poultry Live Attenuated Vaccine Revenue (US$ Million) by Application (2021-2032) Figure 35. US Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032 Figure 36. Canada Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032 Figure 37. Mexico Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032 Figure 38. Europe Poultry Live Attenuated Vaccine Revenue YoY (US$ Million), 2021-2032 Figure 39. Europe Top 5 Players Poultry Live Attenuated Vaccine Revenue (US$ Million) in 2025 Figure 40. Europe Poultry Live Attenuated Vaccine Revenue (US$ Million) by Application (2021-2032) Figure 41. Germany Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032 Figure 42. France Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032 Figure 43. U.K. Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032 Figure 44. Italy Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032 Figure 45. Russia Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032 Figure 46. Asia-Pacific Poultry Live Attenuated Vaccine Revenue YoY (US$ Million), 2021-2032 Figure 47. Asia-Pacific Top 8 Players Poultry Live Attenuated Vaccine Revenue (US$ Million) in 2025 Figure 48. Asia-Pacific Poultry Live Attenuated Vaccine Revenue (US$ Million) by Application (2021-2032) Figure 49. Indonesia Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032 Figure 50. Japan Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032 Figure 51. South Korea Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032 Figure 52. Australia Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032 Figure 53. India Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032 Figure 54. Indonesia Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032 Figure 55. Vietnam Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032 Figure 56. Malaysia Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032 Figure 57. Philippines Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032 Figure 58. Singapore Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032 Figure 59. Central and South America Poultry Live Attenuated Vaccine Revenue YoY (US$ Million), 2021-2032 Figure 60. Central and South America Top 5 Players Poultry Live Attenuated Vaccine Revenue (US$ Million) in 2025 Figure 61. Central and South America Poultry Live Attenuated Vaccine Revenue (US$ Million) by Application (2021-2032) Figure 62. Brazil Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032 Figure 63. Argentina Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032 Figure 64. Middle East and Africa Poultry Live Attenuated Vaccine Revenue YoY (US$ Million), 2021-2032 Figure 65. Middle East and Africa Top 5 Players Poultry Live Attenuated Vaccine Revenue (US$ Million) in 2025 Figure 66. Middle East and Africa Poultry Live Attenuated Vaccine Revenue (US$ Million) by Application (2021-2032) Figure 67. GCC Countries Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032 Figure 68. Israel Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032 Figure 69. Egypt Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032 Figure 70. South Africa Poultry Live Attenuated Vaccine Revenue (US$ Million), 2021-2032 Figure 71. Poultry Live Attenuated Vaccine Value Chain Mapping Figure 72. Channels of Distribution (Direct Vs Distribution) Figure 73. Bottom-up and Top-down Approaches for This Report Figure 74. Data Triangulation Figure 75. Key Executives Interviewed
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療/ヘルスケア)の最新刊レポート
QYResearch社の 医薬・ヘルスケア分野 での最新刊レポート本レポートと同じKEY WORD(poultry)の最新刊レポート
よくあるご質問QYResearch社はどのような調査会社ですか?QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。 QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|